Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms. / Klinge, Mette Winther; Haase, Anne-Mette; Mark, Esben Bolvig; Sutter, Nanna; Fynne, Lotte Vinskov; Drewes, Asbjørn Mohr; Schlageter, Vincent; Lund, Sten; Borghammer, Per; Krogh, Klaus.

In: Neurogastroenterology and Motility, Vol. 32, No. 12, e13948, 12.2020.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{a06ddf5855724f76aab05250702776c3,
title = "Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms",
abstract = "BACKGROUND: Gastrointestinal (GI) symptoms are common in patients with diabetes mellitus (DM). The electromagnetic 3D-Transit system allows assessment of regional transit times and motility patterns throughout the GI tract. We aimed to compare GI transit times and detailed motility patterns of the colon in patients with DM and GI symptoms to those of healthy controls (HC). We further aimed to determine whether any abnormalities in motility were reversible by cholinergic stimulation.METHODS: We compared 18 patients with DM with 20 HC by means of the 3D-Transit system. Patients were studied before and during oral administration of 60 mg pyridostigmine.KEY RESULTS: Compared to HC, patients had prolonged gastric emptying (DM: 3.3 hours (interquartile range (IQR) 2.6-4.6); HC: 2.3 hours (IQR 1.7-2.7) (P < .01)), colonic transit time (DM: 52.6 hours (IQR 23.3-83.0); HC: 22.4 hours (IQR 18.9-43.6) (P = .02)), and whole gut transit time (DM: 69.4 hours (IQR 32.9-103.6); HC: 30.3 hours (IQR 25.2-49.9) (P < .01)). In addition, compared to HC, patients had prolonged transit time in the ascending colon (DM: 20.5 hours (IQR 11.0-44.0); HC: 8.0 hours (IQR 3.8-21.0) (P < .05)) and more slow retrograde movements in the colon (DM: 2 movements (IQR 1-4); HC: 1 movement (IQR 0-1) (P = .01)). In patients, pyridostigmine increased the number of bowel movements (P < .01) and reduced small intestine transit times (P < .05).CONCLUSIONS: Patients with DM and GI symptoms have longer than normal GI transit times. This is only partly reversible by pyridostigmine. The increased number of retrograde colonic movements in patients could potentially explain the abnormally long transit time in proximal colon.",
keywords = "acetylcholinesterase inhibitors, colon, diabetes mellitus, gastric emptying, gastrointestinal motility, small intestine",
author = "Klinge, {Mette Winther} and Anne-Mette Haase and Mark, {Esben Bolvig} and Nanna Sutter and Fynne, {Lotte Vinskov} and Drewes, {Asbj{\o}rn Mohr} and Vincent Schlageter and Sten Lund and Per Borghammer and Klaus Krogh",
note = "{\textcopyright} 2020 John Wiley & Sons Ltd.",
year = "2020",
month = dec,
doi = "10.1111/nmo.13948",
language = "English",
volume = "32",
journal = "Neurogastroenterology and Motility Online",
issn = "1365-2982",
publisher = "Wiley-Blackwell Publishing Ltd.",
number = "12",

}

RIS

TY - JOUR

T1 - Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms

AU - Klinge, Mette Winther

AU - Haase, Anne-Mette

AU - Mark, Esben Bolvig

AU - Sutter, Nanna

AU - Fynne, Lotte Vinskov

AU - Drewes, Asbjørn Mohr

AU - Schlageter, Vincent

AU - Lund, Sten

AU - Borghammer, Per

AU - Krogh, Klaus

N1 - © 2020 John Wiley & Sons Ltd.

PY - 2020/12

Y1 - 2020/12

N2 - BACKGROUND: Gastrointestinal (GI) symptoms are common in patients with diabetes mellitus (DM). The electromagnetic 3D-Transit system allows assessment of regional transit times and motility patterns throughout the GI tract. We aimed to compare GI transit times and detailed motility patterns of the colon in patients with DM and GI symptoms to those of healthy controls (HC). We further aimed to determine whether any abnormalities in motility were reversible by cholinergic stimulation.METHODS: We compared 18 patients with DM with 20 HC by means of the 3D-Transit system. Patients were studied before and during oral administration of 60 mg pyridostigmine.KEY RESULTS: Compared to HC, patients had prolonged gastric emptying (DM: 3.3 hours (interquartile range (IQR) 2.6-4.6); HC: 2.3 hours (IQR 1.7-2.7) (P < .01)), colonic transit time (DM: 52.6 hours (IQR 23.3-83.0); HC: 22.4 hours (IQR 18.9-43.6) (P = .02)), and whole gut transit time (DM: 69.4 hours (IQR 32.9-103.6); HC: 30.3 hours (IQR 25.2-49.9) (P < .01)). In addition, compared to HC, patients had prolonged transit time in the ascending colon (DM: 20.5 hours (IQR 11.0-44.0); HC: 8.0 hours (IQR 3.8-21.0) (P < .05)) and more slow retrograde movements in the colon (DM: 2 movements (IQR 1-4); HC: 1 movement (IQR 0-1) (P = .01)). In patients, pyridostigmine increased the number of bowel movements (P < .01) and reduced small intestine transit times (P < .05).CONCLUSIONS: Patients with DM and GI symptoms have longer than normal GI transit times. This is only partly reversible by pyridostigmine. The increased number of retrograde colonic movements in patients could potentially explain the abnormally long transit time in proximal colon.

AB - BACKGROUND: Gastrointestinal (GI) symptoms are common in patients with diabetes mellitus (DM). The electromagnetic 3D-Transit system allows assessment of regional transit times and motility patterns throughout the GI tract. We aimed to compare GI transit times and detailed motility patterns of the colon in patients with DM and GI symptoms to those of healthy controls (HC). We further aimed to determine whether any abnormalities in motility were reversible by cholinergic stimulation.METHODS: We compared 18 patients with DM with 20 HC by means of the 3D-Transit system. Patients were studied before and during oral administration of 60 mg pyridostigmine.KEY RESULTS: Compared to HC, patients had prolonged gastric emptying (DM: 3.3 hours (interquartile range (IQR) 2.6-4.6); HC: 2.3 hours (IQR 1.7-2.7) (P < .01)), colonic transit time (DM: 52.6 hours (IQR 23.3-83.0); HC: 22.4 hours (IQR 18.9-43.6) (P = .02)), and whole gut transit time (DM: 69.4 hours (IQR 32.9-103.6); HC: 30.3 hours (IQR 25.2-49.9) (P < .01)). In addition, compared to HC, patients had prolonged transit time in the ascending colon (DM: 20.5 hours (IQR 11.0-44.0); HC: 8.0 hours (IQR 3.8-21.0) (P < .05)) and more slow retrograde movements in the colon (DM: 2 movements (IQR 1-4); HC: 1 movement (IQR 0-1) (P = .01)). In patients, pyridostigmine increased the number of bowel movements (P < .01) and reduced small intestine transit times (P < .05).CONCLUSIONS: Patients with DM and GI symptoms have longer than normal GI transit times. This is only partly reversible by pyridostigmine. The increased number of retrograde colonic movements in patients could potentially explain the abnormally long transit time in proximal colon.

KW - acetylcholinesterase inhibitors

KW - colon

KW - diabetes mellitus

KW - gastric emptying

KW - gastrointestinal motility

KW - small intestine

UR - http://www.scopus.com/inward/record.url?scp=85088167098&partnerID=8YFLogxK

U2 - 10.1111/nmo.13948

DO - 10.1111/nmo.13948

M3 - Journal article

C2 - 32688448

VL - 32

JO - Neurogastroenterology and Motility Online

JF - Neurogastroenterology and Motility Online

SN - 1365-2982

IS - 12

M1 - e13948

ER -